期刊
LUNG CANCER MANAGEMENT
卷 3, 期 1, 页码 67-75出版社
FUTURE MEDICINE LTD
DOI: 10.2217/LMT.13.72
关键词
-
资金
- NCI NIH HHS [K12 CA132783] Funding Source: Medline
The PI3K/AKT/mTOR pathway is commonly activated in non-small-cell lung cancer. It plays important roles in promoting oncogenesis in lung cancer and mediating resistance to EGF receptor tyrosine kinase inhibitors. Targeted agents against the components of this pathway are currently in development and their clinical benefits remain to be defined. This review provides an overview of the pathway dysregulation and novel agents targeting the pathway in lung cancer. In addition, potential predictive biomarkers guiding patient selection for targeted PI3K/AKT/mTOR inhibition is also discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据